The Business Research Company’s report on the Necrotizing Enterocolitis Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the necrotizing enterocolitis market?
The increasing cases of premature births are expected to propel the growth of the necrotizing enterocolitis market going forward. Premature births, also known as preterm births, refer to the delivery of a baby before 37 weeks of gestation, compared to the typical 40-week pregnancy term. The increasing cases of premature births are due to maternal health conditions such as high blood pressure, diabetes, and infections, which increase the risk of preterm labor, and lifestyle factors, including smoking, drug use, and poor nutrition, contribute to a higher likelihood of premature births. Rising premature births lead to more cases of necrotizing enterocolitis (NEC) as premature infants have immature gastrointestinal systems, increasing susceptibility to inflammation and infection. For instance, in January 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, premature births account for 8.67% of total births in the United States annually. Therefore, increasing cases of premature births are driving the growth of the necrotizing enterocolitis market.
Access Your Free Sample of the Global Necrotizing Enterocolitis Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp
How has the necrotizing enterocolitis market size evolved, and what are the latest forecasts for its expansion?
The necrotizing enterocolitis market size has grown strongly in recent years. It will grow from $4.83 billion in 2024 to $5.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to the rising occurrence of necrotizing enterocolitis, increasing populations, increasing per capita income, increasing government funding, and increasing cases of premature births.
The necrotizing enterocolitis market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the rising expense of healthcare, the incidence and prevalence of ulcerative colitis (UC), the increase in gastrointestinal diseases, the increase in the number of geriatric and obese people, and the expanding geriatric population. Major trends in the forecast period include advancements in biomarker research for early NEC detection, developments in non-invasive testing methods, adoption of advanced monitoring systems, advancements in surgical techniques, and development of targeted therapies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp
Which major companies dominate the necrotizing enterocolitis market?
Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.
What trends will shape the future of the necrobiosis lipoidica diabeticorum (nld) market?
Major companies operating in the necrotizing enterocolitis market are focusing on developing innovative product solutions, such as cell-free sterile biologic solutions, to address the critical unmet need for effective treatments and improve outcomes in premature infants. A cell-free sterile biologic solution is a purified, sterile liquid containing bioactive molecules such as proteins, growth factors, and cytokines derived from cultured cells but without any intact cells, designed to promote healing and reduce inflammation. For instance, in December 2023, Noveome Biotherapeutics, Inc., a US-based biopharmaceutical company, received notification from the U.S. Food and Drug Administration (FDA), allowing the company to proceed with its Phase 1-2 clinical trial for ST266, a novel biologic aimed at treating necrotizing enterocolitis (NEC) in premature infants. It marks a significant milestone as ST266 is anticipated to be the first major therapeutic advancement for NEC in over 30 years, addressing a critical medical need given the disease’s high morbidity and mortality rates among vulnerable populations.
Which region dominates the necrotizing enterocolitis market, and what factors contribute to its leadership?
North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report
How is the necrotizing enterocolitis market segmented, and which segment holds the largest share?
The necrotizing enterocolitis market covered in this report is segmented –
1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments
2) By Diagnosis: Laboratory Tests, Imaging Techniques
3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)
4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics
Subsegments:
1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN
2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques
3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates
4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC
5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques
6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068
How is the necrotizing enterocolitis market defined?
Necrotizing enterocolitis (NEC) is a serious, potentially life-threatening gastrointestinal condition that primarily affects premature infants. It involves the inflammation and death (necrosis) of the tissue in the intestines, which can lead to perforation, infection, and other complications. The common symptoms of necrotizing enterocolitis include feeding intolerance, abdominal distension, vomiting, and changes in bowel movements.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
